What have we learned from pharmacokinetic and pharmacodynamic theories?
about
Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externaVentilator-associated pneumonia: diagnosis, treatment, and preventionEfficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral doseAntibiotic exposure as a risk factor for emergence of resistance: the influence of concentration.Changes in prescribed drug doses after market introduction.Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration in Hanwoo, Korean native cattleFluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Penetration of moxifloxacin into the human aqueous humour after oral administration.Delivering antibacterials to the lungs: considerations for optimizing outcomes.Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.Ventilator-associated pneumonia: a review.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.10 years' experience with the pneumococcal quinolone moxifloxacin.Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Bacteraemic pneumococcal pneumonia: current therapeutic options.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Pharmacological aspects of the antibiotics used for urological diagnostic procedures.Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease.Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureusImpact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniaeFluoroquinolone pharmacodynamics.Exploring the role of the immune response in preventing antibiotic resistance.Prevalence, toxin gene profile, antibiotic resistance, and molecular characterization of Clostridium perfringens from diarrheic and non-diarrheic dogs in South Korea.
P2860
Q24813204-59CB8E6B-CAAA-4B8A-98E1-FE56D0BDECC7Q28278182-F1AD5DD1-4325-4236-A7D3-986E9A1D5B2AQ29012676-828000DC-39E3-4055-A933-F0F5D13FD3B8Q33739099-B889E34B-5E54-48C1-846F-F99C084C28ACQ34230275-C58D111E-7B21-4F3A-B85E-81CE838D62EFQ34631455-20610E4C-8EEE-4864-9415-4A4A6ADBBD2EQ34994259-32B20272-6EDB-4ED9-9843-71769609D4C5Q35099758-F45A3222-A5DB-41AF-85FB-BD920E25CEDCQ35127800-974B893E-768D-4124-8195-3604C42612EDQ35127877-1991C276-9880-487B-A4E1-1500CEC2C964Q35139691-35075078-CEAE-42EC-83B4-F0CCC4AC5568Q35201049-2B7AE137-ED65-4513-92F2-9BEDC518A188Q35252498-D083CBFE-6BE2-41FF-93EF-3420F6E26CE3Q35547236-8C825079-0054-4416-ACCA-12F3A84468ABQ35593192-ED4DEE14-ABE7-48A8-9B08-91C6C19C6DA3Q35627814-4367C5A1-B18E-43B6-827C-15FFEE56EB52Q35685485-A8C94369-2EA8-4337-88BF-75DEA1BFB7BAQ36162355-2EE67599-CD16-4DDE-8205-B9C8BBDFE900Q36437749-083A417A-400A-495C-AF12-D307F55A7EDDQ36541263-1AA0F5E1-5ADB-4DC8-897E-044FACE4EE1DQ37124090-70619216-E3AD-469E-884A-3DFD8DD86EF4Q37144843-68AE9345-18D6-48ED-87D5-02AF5FB02542Q37579919-EDF8AB62-9AC3-42A7-B69E-24B5F85B9FD0Q37712966-EBCB700B-EFDB-4A67-A5CF-5FE0F3A3D47FQ37833059-DB5F0919-91D4-4F69-B4DB-635E5C36A71CQ37867260-0E081205-DDC4-4E1C-9731-7B6E1D0DEA07Q38253258-12748821-DA0A-4644-BD87-5C5E673CA45FQ39078187-F3AC19B6-D753-432E-8D6A-2CF1DA0D8374Q39616905-C1A3E746-D94D-4C1B-B88A-D09393ACCAECQ39650985-FFB1693F-0D32-46BC-B94E-364460CCDE7AQ40903164-ADDEC69D-AA93-4D72-BD4F-6FBD9EB84B3EQ42727129-AFCCC91B-E02D-40F6-B913-928E669B7916Q42852778-9EED8873-8F00-4FC3-B956-294C49662EA3Q43801621-55029D01-5D89-43A2-AF57-F8A107158B66Q44028719-CAAEB7AC-81F2-4195-BB45-897DB8C1E52FQ53081479-4E5758B0-6B7C-41A0-AF4F-76C032DCB0CF
P2860
What have we learned from pharmacokinetic and pharmacodynamic theories?
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
What have we learned from pharmacokinetic and pharmacodynamic theories?
@ast
What have we learned from pharmacokinetic and pharmacodynamic theories?
@en
What have we learned from pharmacokinetic and pharmacodynamic theories?
@nl
type
label
What have we learned from pharmacokinetic and pharmacodynamic theories?
@ast
What have we learned from pharmacokinetic and pharmacodynamic theories?
@en
What have we learned from pharmacokinetic and pharmacodynamic theories?
@nl
prefLabel
What have we learned from pharmacokinetic and pharmacodynamic theories?
@ast
What have we learned from pharmacokinetic and pharmacodynamic theories?
@en
What have we learned from pharmacokinetic and pharmacodynamic theories?
@nl
P2093
P356
P1476
What have we learned from pharmacokinetic and pharmacodynamic theories?
@en
P2093
Gilliland KK
Paladino JA
Schentag JJ
P304
P356
10.1086/319375
P407
P478
32 Suppl 1
P577
2001-03-01T00:00:00Z